Výsledky vyhledávání - "Bregje M Koomen"

Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity

Autor: Bregje M. Koomen, Mirthe de Boer, Carmen van Dooijeweert, Anne S. R. van Lindert, Ivette A. G. Deckers, Quirinus J. M. Voorham, Stefan M. Willems

Publikováno v: Virchows Archiv, 707–720. SPRINGER

Programmed death ligand-1 (PD-L1) immunostaining, which aids clinicians in decision-making on immunotherapy for non-small cell lung cancer (NSCLC) patients, is sometimes performed on cytological specimens. In this study, differences in cytology fixat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd2015ab99de6706def86ddfa8e43ea8
https://doi.org/10.1007/s00428-022-03446-w

Zobrazit plný text záznamu

Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients

Autor: Quirinus J. M. Voorham, Chantal C H J Epskamp-Kuijpers, Bregje M Koomen, Stefan M. Willems, Carmen van Dooijeweert, Ivette A. G. Deckers, Anne S R van Lindert

Publikováno v: Lung Cancer, 159, 117-126. ELSEVIER IRELAND LTD

Objectives: Immunohistochemical expression of programmed death-ligand 1 (PD-L1) is used as a predictive biomarker for prescription of immunotherapy to non-small cell lung cancer (NSCLC) patients. Accurate assessment of PD-L1 expression is therefore c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93284a2cde17c2f4d313693bce96e273
https://doi.org/10.1016/j.lungcan.2021.07.012

Zobrazit plný text záznamu

Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non–small cell lung cancer

Autor: Bregje M Koomen, Nils A. 't Hart, Wim Timens, Stefan M. Willems, Judith M. Vonk, Jose van der Starre-Gaal, Kim Monkhorst, Jacqueline J C van der Meij, Jan H. von der Thüsen

Publikováno v: Cancer Cytopathology
Cancer cytopathology, 129(4), 304-317. Wiley
Cancer cytopathology, 129(4), 304-317. Wiley-Blackwell

Background Immunohistochemical staining of programmed death‐ligand 1 (PD‐L1) is used to determine which patients with non–small cell lung cancer (NSCLC) may benefit most from immunotherapy. Therapeutic management of many patients with NSCLC is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d52ac6a19a17afc0ce0209199c6617c
https://pure.eur.nl/en/publications/e93587c4-9710-4365-ba77-801c8bc23f84

Zobrazit plný text záznamu

Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity

Autor: Bregje M, Koomen, Mirthe, de Boer, Carmen, van Dooijeweert, Anne S R, van Lindert, Ivette A G, Deckers, Quirinus J M, Voorham, Stefan M, Willems

Publikováno v: Virchows Archiv : an international journal of pathology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3cef56e44bcc2a412bbc055b1a480921
https://pubmed.ncbi.nlm.nih.gov/36370167

Zobrazit plný text záznamu

False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients

Autor: Aryan Vink, Juergen Hoelters, Stefan M. Willems, Emma J de Ruiter, Bregje M Koomen, Willem Vreuls, Mirthe de Boer

Publikováno v: Histopathology

AIMS Programmed death-ligand 1 (PD-L1) immunostaining is used to predict which non-small-cell lung cancer (NSCLC) patients will respond best to treatment with programmed cell death protein 1/PD-L1 inhibitors. PD-L1 immunostaining is sometimes perform

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13dcd063ce84fb6297ef41776de27ffb
https://pubmed.ncbi.nlm.nih.gov/33772818

Zobrazit plný text záznamu

Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)

Autor: Emma J, de Ruiter, Frans J, Mulder, Bregje M, Koomen, Ernst-Jan, Speel, Mari F C M, van den Hout, Reinout H, de Roest, Elisabeth, Bloemena, Lot A, Devriese, Stefan M, Willems

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 34(6)

Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Several antibodies are available for PD-L1 testing and multiple staining and scoring method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7d34a3847ddd2ee89b4c35595a71bd64
https://pubmed.ncbi.nlm.nih.gov/32759978

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání